14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
NEON vs NERV: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
NERV Captures Overall Composite Edge (43.3 HOLD vs 39.8 SELL), While NEON Leads 4–1 on Growth & Valuation Pillars
NERV Overall Winner
6-Pillar Tally: NEON 4 – 1 NERV (1 Tie)
Matrix Metrics: NEON 5 – 5 NERV
As of Nov 20, 2026, Minerva Neurosciences, Inc (NERV) captures the overall head-to-head institutional edge over Neonode Inc. (NEON) on higher Unified Composite conviction (43.3/100 HOLD vs. 39.8/100 SELL) after splitting the core matrix 5–5 (led by Growth & Scale), while NEON wins 4–1 across the 6-pillar growth and valuation breakdown. NEON trades at $0.48 (9.3x Forward P/E, -604.4% operating margin) versus NERV at $2.00 (11.2x Forward P/E, 0.0% operating margin).
Growth vs. Quality Trade-Off: NERV earns the overall head-to-head edge with a stronger Unified Composite Score (43.3/100 HOLD vs. NEON 39.8/100 SELL) and 1.63β · 76% Vol risk profile, whereas NEON leads top-line expansion (-20.4% YoY revenue growth, 0.37x PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: NEON is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 22.0); meanwhile NERV is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 33.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on NEON vs NERV. Trailing 12-month operating profitability (NEON -604.4% vs NERV 0.0%) and valuation multiples (NEON 9.3x vs NERV 11.2x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Electronic Components value chain with $8.7M market capitalization and -604.4% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
NERV Moat ProfileCyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $105.7M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ NEON vs NERV Key Questions & Quantitative Answers
As of Nov 20, 2026, Minerva Neurosciences, Inc (NERV) captures the overall head-to-head institutional edge over Neonode Inc. (NEON) on higher Unified Composite conviction (43.3/100 HOLD vs. 39.8/100 SELL) after splitting the core matrix 5–5 (led by Growth & Scale), while NEON wins 4–1 across the 6-pillar growth and valuation breakdown. NEON trades at $0.48 (9.3x Forward P/E, -604.4% operating margin) versus NERV at $2.00 (11.2x Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: NERV earns the overall head-to-head edge with a stronger Unified Composite Score (43.3/100 HOLD vs. NEON 39.8/100 SELL) and 1.63β · 76% Vol risk profile, whereas NEON leads top-line expansion (-20.4% YoY revenue growth, 0.37x PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: NEON is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 22.0); meanwhile NERV is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 33.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
NERV leads the Growth & Scale pillar: NEON posts -20.4% YoY revenue growth and +0.0% YoY earnings growth on $2.0M TTM revenue (98.8% gross margin, -604.4% operating margin), compared with NERV at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, NEON generates $2.0M in USD-normalized revenue versus N/A for NERV. In operating R&D and SG&A reinvestment, NEON deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for NERV.
NEON screens cheaper on headline valuation multiples. NEON trades at 9.3x Forward P/E, 9.3x Trailing P/E, 0.37x PEG, and N/M EV/Revenue (unreported FCF margin), whereas NERV trades at 11.2x Forward P/E, 11.2x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against NEON (46.8% ROE) versus NERV (-675.1% ROE) capital efficiency.
In options market volatility and institutional positioning, NEON carries 77.8% implied volatility (50th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.07β · 63% Vol realized risk). By comparison, NERV carries 194.3% implied volatility (100th %ile, Extreme (>80th %ile)), a 6.67x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.63β · 76% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.